Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Equity Income (2024 - 2025)

Historic Equity Income for Ani Pharmaceuticals (ANIP) over the last 2 years, with Q3 2025 value amounting to $3.1 million.

  • Ani Pharmaceuticals' Equity Income rose 13173.43% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $560000.0, marking a year-over-year decrease of 9325.14%. This contributed to the annual value of $6.3 million for FY2024, which is N/A changed from last year.
  • Per Ani Pharmaceuticals' latest filing, its Equity Income stood at $3.1 million for Q3 2025, which was up 13173.43% from $332000.0 recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Equity Income peaked at $9.7 million during Q1 2024, and registered a low of -$2.7 million during Q2 2024.